Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Wyles, David L.; Ruane, Peter; Sulkowski, Mark S.; Dieterich, Douglas T.; Luetkemeyer, Anne F; Morgan, Timothy R.; Sherman, Kenneth E.; Dretler, Robin; Fishbein, Dawn; Gathe, Joseph; Henn, Sarah; Hinestrosa, Federico; Huynh, Charles; McDonald, Cheryl; Mills, Anthony; Overton, Edgar Turner; Ramgopal, Moti; Rashbaum, Bruce; Ray, Graham; Scarsella, Anthony; Yozviak, Joseph L; McPhee, Fiona; Liu, Zhaohui; Hughes, Eric; Yin, Philip D.; Noviello, Stephanie; Ackerman, Peter

doi:10.1056/nejmoa1503153

Cited by 386 publications

(328 citation statements)

References 32 publications

Supporting

Mentioning

289

Contrasting

Unclassified

Order By: Relevance

“…However, its interactions with specific ART drugs and regimens are being studied and dose modification recommendations are being finalized. 23 Table 1 highlights drug-drug interactions between DAA and some commonly prescribed medications. The University of Liverpool website, www.…”

Section: Daclatasvir (Dcv)mentioning

confidence: 99%

“…23,54 While SOF/RBV therapy has excellent efficacy in HCV GT-2, many patients may not be able to tolerate RBV. These patients may benefit from combination therapy with DCV and SOF.…”

Section: Genotypementioning

confidence: 99%

“…The study showed a SVR at 12 weeks (SVR12) of 96% with 12-week combination therapy, but in case of 8-week therapy, the SVR12 was only 76%. 23 Many HCV and HIV coinfected patients may be on antiretroviral agents, which may not allow recommended DAA regimen to be used. Switching of HAART may be associated with a risk of viral breakthrough.…”

Section: Management Of Hcv In Hiv Coinfectionmentioning

confidence: 99%

See 2 more Smart Citations

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Daclatasvir (Dcv)mentioning

confidence: 99%

“…23,54 While SOF/RBV therapy has excellent efficacy in HCV GT-2, many patients may not be able to tolerate RBV. These patients may benefit from combination therapy with DCV and SOF.…”

Section: Genotypementioning

confidence: 99%

Section: Management Of Hcv In Hiv Coinfectionmentioning

confidence: 99%

See 1 more Smart Citation

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…This decline will be further accelerated by the recent impressive improvement of efficacy of treatments for HCV chronic infection. Recent trials have shown that the current available interferon-free therapeutic regimens with the new direct-acting antiviral agents (DAAs) reach the sustained virological response in more than 90% of patients with cirrhosis, either naïve, relapsers or null responders to Interferon-based regimes, both HCV-monoinfected [30][31][32][33] and HCV/HIV coinfected [34][35][36]. A further impressive reduction of HCV-related mortality rate for liver cirrhosis is expected by a larger use of second and third generation DAAs.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

Stroffolini

Sagnelli

Gaeta

et al. 2017

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…The recommendation is based on the ALLY-2 trial which assessed the efficacy and safety of daclatasvir and sofosbuvir for 12 weeks in HIV and HCV co-infected patients [18]. SVR rate was 96% in treatment naive patients and 82% in treatment-experienced patients.…”

Section: Genotypementioning

confidence: 99%

New treatments for chronic hepatitis C infection

Yapalı¹,

Tözün²

2016

MMJ

View full text Add to dashboard Cite

The goal of HCV treatment is to prevent cirrhosis, hepatocellular carcinoma, liver-related deaths. The development of direct-acting antiviral (DAA) agents which target various steps in HCV lifecycle led to a revolution by providing nearly complete eradication of HCV. The new treatment regimens with high cure rates have changed the standards of care in the regions where patients have access to new treatments. This review addresses the recent updates in management of chronic hepatitis C infection. Keywords: Hepatitis C, New treatments, Direct antiviral agents ÖZHepatit C tedavisinde amaç siroz, siroza bağlı komplikasyonları ve hepatosellüler karsinoma gelişmesi risklerini azaltmak veya tamamiyle ortadan kaldırmaktır. HCV tedavisinde son yıllarda çok önemli gelişmeler kaydedilmiştir. Yeni geliştirilen ve HCV virusunun çoğalmasını engelleyen direkt etkili antiviral ilaçlar ile tama yakın oranlarda virusun eradikasyonu sağlanmaktadır. Bu derlemede yeni geliştirilen bu ilaçlar ile tedaviler detaylı olarak ele alınacaktır.

show abstract

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Cited by 386 publications

References 32 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

New treatments for chronic hepatitis C infection

Contact Info

Product

Resources

About